Why Lilly is betting on peripheral pain biology with the 4E Therapeutics acquisition
Find out how Lilly’s 4E Therapeutics deal could advance non-opioid chronic pain drugs and what risks remain.
Pharma & Biotech
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.